Foyston Gordon & Payne Inc Buys 11,089 Shares of ICON Public Limited (NASDAQ:ICLR)

Foyston Gordon & Payne Inc lifted its stake in ICON Public Limited (NASDAQ:ICLR - Free Report) by 27.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,713 shares of the medical research company's stock after purchasing an additional 11,089 shares during the period. ICON Public accounts for approximately 2.9% of Foyston Gordon & Payne Inc's holdings, making the stock its 12th largest holding. Foyston Gordon & Payne Inc owned about 0.06% of ICON Public worth $10,845,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Steph & Co. increased its position in shares of ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company's stock valued at $327,000 after acquiring an additional 55 shares during the last quarter. Private Trust Co. NA increased its position in shares of ICON Public by 48.8% in the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company's stock valued at $52,000 after acquiring an additional 82 shares during the last quarter. Sierra Ocean LLC acquired a new stake in shares of ICON Public in the fourth quarter valued at about $29,000. Park Place Capital Corp increased its position in shares of ICON Public by 281.4% in the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company's stock valued at $47,000 after acquiring an additional 166 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock valued at $91,000 after acquiring an additional 169 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

ICON Public Stock Performance

Shares of NASDAQ:ICLR traded up $6.26 during trading on Monday, reaching $140.22. 1,723,922 shares of the stock were exchanged, compared to its average volume of 1,011,877. ICON Public Limited has a 12 month low of $133.28 and a 12 month high of $347.72. The firm has a market cap of $11.32 billion, a PE ratio of 14.71, a PEG ratio of 1.86 and a beta of 1.23. The stock has a 50-day moving average price of $159.00 and a 200-day moving average price of $189.41. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical research company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.17 by $0.02. The business had revenue of $2 billion during the quarter, compared to analysts' expectations of $2.03 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The firm's revenue for the quarter was down 4.3% compared to the same quarter last year. During the same period in the previous year, the company posted $3.47 earnings per share. Research analysts expect that ICON Public Limited will post 13.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ICLR. Citigroup lowered their target price on ICON Public from $290.00 to $215.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Barclays reduced their price target on ICON Public from $165.00 to $155.00 and set an "equal weight" rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group reduced their price target on ICON Public from $180.00 to $160.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Mizuho reduced their price target on ICON Public from $238.00 to $200.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Finally, TD Cowen cut ICON Public from a "buy" rating to a "hold" rating and reduced their price target for the stock from $254.00 to $157.00 in a report on Monday, April 14th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, ICON Public presently has an average rating of "Moderate Buy" and a consensus target price of $215.33.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.